Published in N Engl J Med on June 03, 1999
Nonmyeloablative Haploidentical Transplant Followed by MLN9708 | NCT02169791
Graft-versus-host disease. Lancet (2009) 8.78
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant (2008) 7.10
Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol (2012) 3.50
IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest (2000) 3.19
Acute graft-versus-host disease: from the bench to the bedside. Blood (2009) 2.24
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood (2006) 1.93
Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol (2012) 1.63
Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood (2005) 1.54
The role of B7 family molecules in hematologic malignancy. Blood (2012) 1.47
CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest (2000) 1.27
Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD). Philos Trans R Soc Lond B Biol Sci (2005) 1.26
Hematopoietic chimerism and central tolerance created by peripheral-tolerance induction without myeloablative conditioning. J Clin Invest (2003) 1.25
Renal allograft rejection is prevented by adoptive transfer of anergic T cells in nonhuman primates. J Clin Invest (2005) 1.24
Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol (2015) 1.17
Cutting edge: Receptors for C3a and C5a modulate stability of alloantigen-reactive induced regulatory T cells. J Immunol (2013) 1.13
Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res (2010) 1.10
Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. Blood (2008) 1.07
Blockade of LIGHT/LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. J Clin Invest (2002) 1.07
Current status of haploidentical stem cell transplantation for leukemia. J Hematol Oncol (2008) 1.05
Alloreactive and leukemia-reactive T cells are preferentially derived from naive precursors in healthy donors: implications for immunotherapy with memory T cells. Haematologica (2011) 1.04
Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. Sci Transl Med (2015) 1.04
Challenges to achieving clinical transplantation tolerance. J Clin Invest (2001) 1.03
Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment. Stem Cells Transl Med (2012) 1.02
Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells. Front Immunol (2014) 1.01
Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies. World J Transplant (2013) 0.98
CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors. Biol Blood Marrow Transplant (2008) 0.96
Current and future approaches for control of graft-versus-host disease. Expert Rev Hematol (2008) 0.95
Transplantation tolerance: lessons from experimental rodent models. Transpl Int (2007) 0.94
Molecular and functional characterization of allogantigen-specific anergic T cells suitable for cell therapy. Haematologica (2010) 0.93
Recent advances in the treatment of graft-versus-host disease. Clin Med Res (2004) 0.92
Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors. Bone Marrow Transplant (2008) 0.92
Haploidentical transplantation for hematologic malignancies: where do we stand? Hematology Am Soc Hematol Educ Program (2012) 0.92
Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther (2010) 0.91
Induction of alloanergy in human donor T cells without loss of pathogen or tumor immunity. Transplantation (2008) 0.91
The contributions of T-cell anergy to peripheral T-cell tolerance. Immunology (2001) 0.91
Haploidentical transplantation for leukemia. Curr Oncol Rep (2010) 0.89
T-cell costimulatory molecules in acute-graft-versus host disease: therapeutic implications. Bone Marrow Res (2010) 0.87
The blockade of T-cell co-stimulation as a therapeutic stratagem for immunosuppression: Focus on belatacept. Biologics (2007) 0.87
Clinical Outlook for Type-1 and FOXP3(+) T Regulatory Cell-Based Therapy. Front Immunol (2015) 0.86
Pilot study of a (213)bismuth-labeled anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation. Transplantation (2010) 0.85
Ex vivo inhibition of NF-kappaB signaling in alloreactive T-cells prevents graft-versus-host disease. Am J Transplant (2009) 0.84
NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT. Blood (2015) 0.83
Expansion of allospecific regulatory T cells after anergized, mismatched bone marrow transplantation. Sci Transl Med (2009) 0.83
Transplantation of haploidentically mismatched stem cells for the treatment of malignant diseases. Springer Semin Immunopathol (2004) 0.82
Accelerating immune reconstitution after hematopoietic stem cell transplantation. Clin Transl Immunology (2014) 0.81
CMV-specific immune reconstitution following allogeneic stem cell transplantation. Virulence (2016) 0.81
Immunotherapy of AML: future directions. J Clin Pathol (2000) 0.80
Lymphoid reconstruction and vaccines. Biol Blood Marrow Transplant (2007) 0.78
Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy. Immunol Rev (2017) 0.78
Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig Dis Sci (2010) 0.78
Alternative Donor Transplantation for Acute Myeloid Leukemia. J Clin Med (2015) 0.78
"No donor"? Consider a haploidentical transplant. Blood Rev (2014) 0.78
Haplo is the new black. Blood (2014) 0.77
Acute graft-versus-host disease: are we close to bringing the bench to the bedside? Best Pract Res Clin Haematol (2013) 0.77
The new immunology--the end of immunosuppressive drug therapy? N Engl J Med (1999) 0.77
T-cell costimulatory blockade in organ transplantation. Cold Spring Harb Perspect Med (2013) 0.77
Advances in haploidentical stem cell transplantation. Rev Bras Hematol Hemoter (2011) 0.77
Allospecific Tregs Expanded After Anergization Remain Suppressive in Inflammatory Conditions but Lack Expression of Gut-homing Molecules. Mol Ther (2016) 0.75
Transplantation of anergic histoincompatible bone marrow cells. N Engl J Med (1999) 0.75
Haploidentical hematopoietic stem-cell transplantation in adults. Bone Marrow Res (2011) 0.75
FOXP3-Positive Regulatory T Cells and Kidney Allograft Tolerance. Am J Kidney Dis (2016) 0.75
Transplantation of anergic histoincompatible bone marrow cells. N Engl J Med (1999) 0.75
Biologics in the prevention and treatment of graft rejection. Springer Semin Immunopathol (2006) 0.75
CD28 Blockade Ex Vivo Induces Alloantigen-Specific Immune Tolerance but Preserves T-Cell Pathogen Reactivity. Front Immunol (2017) 0.75
PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26
Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest (1981) 6.89
The B7 and CD28 receptor families. Immunol Today (1994) 6.38
Characterization of a human B lymphocyte-specific antigen. J Immunol (1980) 5.76
Antigens on human monocytes identified by monoclonal antibodies. J Immunol (1981) 4.67
B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol (1989) 4.61
Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science (1993) 4.45
A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner. EMBO J (1994) 3.88
B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci U S A (1991) 3.84
Replication and plaque formation of mouse hepatitis virus (MHV-2) in mouse cell line DBT culture. Arch Gesamte Virusforsch (1974) 3.24
Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol (1991) 3.12
B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol (1983) 3.09
Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med (1991) 3.08
Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol (2001) 2.97
B7, a B-cell-restricted antigen that identifies preactivated B cells. J Immunol (1987) 2.92
Characterization of a human B cell-specific antigen (B2) distinct from B1. J Immunol (1981) 2.86
Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol (1994) 2.77
Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci U S A (1993) 2.76
Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood (1984) 2.74
Adhesion of human B cells to germinal centers in vitro involves VLA-4 and INCAM-110. Science (1990) 2.69
Characterization of CTLA-4 structure and expression on human T cells. J Immunol (1993) 2.68
BLAST-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein Barr virus. J Immunol (1985) 2.66
Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. Blood (2000) 2.65
Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature (1992) 2.55
Stages of B cell differentiation in human lymphoid tissue. J Exp Med (1981) 2.49
B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity (1995) 2.45
CTLA-4 regulates induction of anergy in vivo. Immunity (2001) 2.39
CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest (1997) 2.39
Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Clin Invest (1981) 2.34
Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. Science (1997) 2.33
Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A (1998) 2.29
Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol Oncol (2001) 2.20
Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J Immunol (2000) 2.16
Analysis of genomic and intracellular viral RNAs of small plaque mutants of mouse hepatitis virus, JHM strain. Virology (1984) 2.13
Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol (2001) 2.12
Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science (1994) 2.10
The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity (1999) 2.06
Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proc Natl Acad Sci U S A (1993) 2.03
Hairy cell leukemia: splenectomy after alpha 2b-interferon therapy. Blood (1991) 2.01
Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med (1991) 1.98
Epstein-Barr virus superinduces a new human B cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts. Cell (1982) 1.95
Monoclonal antibodies defining serologically distinct HLA-D/DR related Ia-like antigens in man. Hum Immunol (1981) 1.94
A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest (1981) 1.93
Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex. Proc Natl Acad Sci U S A (1992) 1.92
Expression of cell surface markers after human B lymphocyte activation. Proc Natl Acad Sci U S A (1981) 1.91
Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J Exp Med (1993) 1.81
CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci U S A (1995) 1.80
Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation. Proc Natl Acad Sci U S A (1996) 1.80
The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Immunol Rev (1996) 1.76
Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci U S A (1995) 1.75
p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat Med (2000) 1.73
Isolated human follicular dendritic cells display a unique antigenic phenotype. J Exp Med (1989) 1.72
Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci U S A (1993) 1.72
Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant (2010) 1.68
Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res (1980) 1.66
Researches on Vaccine Virus in Vitro with Special References to its Affinity for Nerve Tissue. Am J Pathol (1925) 1.65
Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia (2009) 1.63
B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med (1993) 1.63
Array-based DNA methylation profiling in follicular lymphoma. Leukemia (2009) 1.63
HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J Immunol (1986) 1.63
Persistent, tolerant or subacute infection in Borna disease virus-infected rats. J Gen Virol (1983) 1.62
High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol (1998) 1.61
Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. J Immunol (1994) 1.61
The role of radiotherapy in the management of operable locally advanced breast carcinoma: results of a randomized trial by the Eastern Cooperative Oncology Group. Cancer (1997) 1.60
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage. Blood (1981) 1.57
Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant (2000) 1.57
Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood (1998) 1.55
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study. Cancer J (2000) 1.55
Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients. Acta Haematol (1994) 1.55
Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood (1998) 1.52
B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation. J Clin Invest (1984) 1.51
Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol (2011) 1.51
Characteristics and outcome of children with Beckwith-Wiedemann syndrome and Wilms' tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol (2000) 1.50
The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor. J Immunol (1998) 1.49
Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promoter. Tissue Antigens (1998) 1.46
Prognostic implications of c-Ki-ras2 mutations in patients with advanced colorectal cancer treated with 5-fluorouracil and interferon: a study of the eastern cooperative oncology group (EST 2292) Cancer J Sci Am (1997) 1.45
Monoclonal antibody identifies a new Ia-like (p29,34) polymorphic system linked to the HLA-D/DR region. Nature (1981) 1.45
Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol (1999) 1.45